Mathew Carter
@mathew_carter1
Followers
181
Following
594
Statuses
430
Scientific Officer @TheChristie interested in molecular analysis and target therapy in lung cancer.
Manchester, England
Joined February 2018
Systemic treatment among frail older patients with cancer: An observational cohort @WilliamDale_MD @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #Elsevier #GeriatricOncology #GeriatricAssessment #OlderAdults #TreatmentDecisionMaking
0
0
1
Dr. @JordiRemon discusses uncommon #EGFR mutations in NSCLC at #ITCD2025. Afatinib approved here but osimertinib has some activity. Is using PACC a better approach to guiding therapies? Afatinib probably preferred for me in exon 18 but need to manage toxicity aggressively.
0
0
0
The fellows will be lucky to have you both as leaders/mentors. Well done both!
It’s official 💫! @JamieMJWeaver & I will now be co-leading The Christie International Fellowship Programme for Medical Oncology. 🧑⚕️We’re happy to have 40+ clinical fellows across various tumour groups, contributing to cancer care & research. Watch the space…more to come 🌏!
1
1
6
Interesting data. Is anyone not testing their squamous cell population who are never smokers or have less that a 15 pack year history? @MCRCnews @NWGLH @caliraf
Report on NGS in squamous NSCLC @LungCaJournal from Dr. @Joshua_Reuss et al. Detected actionable genomic alterations in 22.2% of patients with squamous NSCLC and no history of smoking including #EGFR and #MET. In those with prior smoking, AGAs in 2.4%.
0
0
3
Real-world analysis of first-line carboplatin, etoposide, atezolizumab for extensive stage #SCLC with ≥3y f/u now @LungCaJournal. In 207 pts, the 3y OS rate was 21%. Need to build on this backbone, but long-term survival is possible for some.
0
0
1
RT @OncLive: The FDA has approved the FoundationOne Liquid CDx for use as a companion diagnostic to identify patients with mNSCLC harboring…
0
1
0
Congratulations @lauramolinerj and co-authors. These real world data are important when discussing with our patients so they can make informed decisions @emhalkyard @philruss3 @caliraf
Excited to share our work on RWE in ES-SCLC: 🎉 First-line chemo-immunotherapy in SCLC: outcomes of a binational real-world study - JTO Clinical and Research Reports @NuriaZellweger @caliraf @RothschildSacha
1
0
2
FDA approved MARIPOSA2: amivantamab plus chemotherapy for #EGFR NSCLC post osimertinib. Adding amivantamab improves PFS (HR 0.48) with encouraging OS trend (HR 0.73, not yet significant).
0
0
3
#ESMO24 Targeting KRAS in NSCLC🔥 Packed session today on this hot topic: - Current status of KRAS G12Ci #NatashaLeighl - KRAS Non G12C #CollinLindsay - Resistance @DrMarkAwad - KRAS/IO combos @DrJNaidoo With great questions from @KRASKickers
#ESMOAmbassadors #ESMO24 @myESMO
0
0
0
Colin Lindsay presenting a future perspective on non-KRAS G12C mutations in NSCLC at #ESMO24. A top down (clinical) and bottom up (preclinical/translation) approach required for breakthroughs. Exciting time for pan ras / pan KRAS inhibitors @DrColinLindsay @mcrRASlab @MCRCnews
0
3
16
NEW content online! Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
1
0
0
RT @hsbalata: Proud day for @WythenshaweHosp @MFTnhs to have successfully performed our first #ION Robotic Bronchoscopy cases. Massive effo…
0
16
0
RT @DrJNaidoo: Intracranial activity of Tarlatamab in 2L SCLC in Ph I DeLLphi-300 Trial @JCO_ASCO: - 152pts, mfollow-up 12.1m - intracrani…
0
19
0
Mariposa study. Congratulations to the authors @caliraf and colleagues and all those who contributed @philruss3. @myESMO @MCRCnews
🫁 MARIPOSA 🫁 🌟 Published @Annals_Oncology 📌 biomarkers of high-risk disease #ASCO24, #8504
@EnriquetaFelip
@myESMO
@EGFRResisters
@EGFRmNSCLC
@EgfrUk
@EGFRResisters
#egfr
#LCSM 📌 The paper is here. (Open access）
0
2
9
RT @StephenVLiu: Phase III ALINA trial of adjuvant alectinib for resected stage Ib-IIIA (AJCC v7) #ALK NSCLC now @NEJM. Compared 2y of alec…
0
34
0
Congratulations Laura @mcrRASlab @mcr
Very proud of @TheChristieNHS Med Onc trainee Laura Woodhouse @mcrRASlab @MCRCnews for winning the @AACR-@abbvie Scholar-in-Training Award 🥇 #AACR24
0
0
1
RT @FDAOncology: FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumo…
0
56
0
RT @JGeriOnc: Immunotherapy use in older adults with cancer with frailty: A young SIOG review paper @WilliamDale_MD…
0
12
0
RT @caliraf: Well done @irrandulfe and @TheChristieNHS team and colleagues. Not a lot of data on this issue
0
1
0